These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1746595)

  • 41. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
    Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
    J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The idiotypic characteristics of human antibodies to factor VIII.
    de la Fuente B; Hoyer LW
    Blood; 1984 Sep; 64(3):672-8. PubMed ID: 6432076
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Idiotypic regulation of anti-factor VIII antibodies.
    Kazatchkine MD; Lacroix-Desmazes S; Moreau A; Kaveri SV
    Haematologica; 2000 Oct; 85(10 Suppl):97-9. PubMed ID: 11187885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains.
    Chaves DG; Velloso-Rodrigues C; Moreau V; Nguyen C; Villard S; Belisário AR; Granier C; Santoro MM
    Br J Haematol; 2008 May; 141(5):708-15. PubMed ID: 18422780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
    Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
    Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin.
    Pall AA; Varagunam M; Adu D; Smith N; Richards NT; Taylor CM; Michael J
    Clin Exp Immunol; 1994 Feb; 95(2):257-62. PubMed ID: 8306501
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence of the direct interaction between spontaneously occurring anti-factor VIII autoantibody and intravenous immunoglobulin.
    Nishida Y; Sakiyama N; Kakishita E; Nagai K
    Nihon Ketsueki Gakkai Zasshi; 1989 Feb; 52(1):134-9. PubMed ID: 2500823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus.
    Lafferty TE; Smith JB; Schuster SJ; DeHoratius RJ
    Arthritis Rheum; 1997 Apr; 40(4):775-8. PubMed ID: 9125263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use.
    Caccavo D; Vaccaro F; Ferri GM; Amoroso A; Bonomo L
    J Autoimmun; 1994 Aug; 7(4):537-48. PubMed ID: 7980854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-idiotypic antibodies and autoantibodies.
    Zanetti M
    Ann N Y Acad Sci; 1983; 418():363-78. PubMed ID: 6608905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.
    Towfighi F; Gharagozlou S; Sharifian RA; Kazemnejad A; Esmailzadeh K; Managhchi MR; Shokri F
    Acta Haematol; 2005; 114(2):84-90. PubMed ID: 16103630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of intravenous immunoglobulin G in autoimmune hematologic disorders.
    Blanchette VS; Kirby MA; Turner C
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):72-82. PubMed ID: 1509297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins.
    Mehta YS; Badakere SS
    J Postgrad Med; 1996; 42(2):46-9. PubMed ID: 9715299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients.
    Reding MT; Lei S; Lei H; Green D; Gill J; Conti-Fine BM
    Thromb Haemost; 2002 Oct; 88(4):568-75. PubMed ID: 12362225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Identification of IgG subclass and FVIII binding epitope of an acquired FVIII inhibitor in a bullous pemphigoid patient].
    Zuo WL; Zhang GS; Qing ZJ; Xu YX; Qin LX; Xu M
    Zhonghua Xue Ye Xue Za Zhi; 2006 Sep; 27(9):593-7. PubMed ID: 17278424
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acquired hemophilia and its treatment.
    Sultan Y
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S15-8. PubMed ID: 9351531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Can intravenous immunoglobulin treatment regulate autoimmune responses?
    Kaveri SV; Dietrich G; Kazatchkine MD
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):64-71. PubMed ID: 1509296
    [No Abstract]   [Full Text] [Related]  

  • 60. Surface immunoglobulins are involved in the interaction of protein A with human B cells and in the triggering of B cell proliferation induced by protein A-containing Staphylococcus aureus.
    Romagnani S; Giudizi MG; Biagiotti R; Almerigogna F; Maggi E; Del Prete G; Ricci M
    J Immunol; 1981 Oct; 127(4):1307-13. PubMed ID: 6974188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.